Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legislation
|
| gptkbp:addressed |
gptkb:thalidomide_tragedy
|
| gptkbp:amended_by |
gptkb:Federal_Food,_Drug,_and_Cosmetic_Act
|
| gptkbp:created |
Drug Efficacy Study Implementation
|
| gptkbp:effective_date |
1962-10-10
|
| gptkbp:enacted_by |
gptkb:legislation
|
| gptkbp:established |
New Drug Application process
safety and effectiveness standards |
| gptkbp:examines |
historical analyses of drug laws
|
| gptkbp:focuses_on |
drug safety
|
| gptkbp:has_impact_on |
pharmaceutical regulations
|
| https://www.w3.org/2000/01/rdf-schema#label |
Drug Amendments of 1962
|
| gptkbp:impact |
drug approval process
|
| gptkbp:includes |
provisions for generic drugs
|
| gptkbp:increased |
FDA authority
|
| gptkbp:influenced |
gptkb:healthcare_organization
subsequent drug legislation |
| gptkbp:influenced_by |
public outcry over drug safety
|
| gptkbp:introduced |
gptkb:legislation
|
| gptkbp:is_analyzed_in |
public health studies
|
| gptkbp:is_aresource_for |
drug-related health crises
|
| gptkbp:is_associated_with |
gptkb:the_FDA
|
| gptkbp:is_cited_in |
discussions on drug policy
|
| gptkbp:is_considered |
a landmark legislation
|
| gptkbp:is_criticized_for |
healthcare debates
potentially delaying drug availability |
| gptkbp:is_discussed_in |
academic literature on drug regulation
|
| gptkbp:is_evaluated_by |
policy reviews
|
| gptkbp:is_linked_to |
the evolution of the FDA's role
|
| gptkbp:is_noted_for |
its impact on drug marketing practices
|
| gptkbp:is_part_of |
the Great Society initiatives
the history of drug regulation in the U. S. the timeline of U. S. drug legislation |
| gptkbp:is_recognized_by |
a pivotal moment in drug regulation history
|
| gptkbp:is_referenced_in |
legal cases regarding drug approval
|
| gptkbp:is_related_to |
drug safety standards
|
| gptkbp:is_standardized_by |
drug manufacturing practices
|
| gptkbp:is_subject_to |
ongoing legal interpretations
|
| gptkbp:is_supported_by |
health advocacy groups
|
| gptkbp:is_used_for |
a case study in regulatory policy.
|
| gptkbp:led_to |
increased consumer protection
greater scrutiny of drug advertising increased costs for drug development |
| gptkbp:passes_through |
gptkb:the_87th_Congress
|
| gptkbp:purpose |
to ensure drug safety and efficacy
|
| gptkbp:regulates |
gptkb:Company
|
| gptkbp:requires |
post-marketing surveillance
clinical trials for new drugs labeling requirements for drugs |
| gptkbp:resulted_in |
more rigorous drug testing
|
| gptkbp:signed_by |
gptkb:John_F._Kennedy
gptkb:President_John_F._Kennedy |
| gptkbp:bfsParent |
gptkb:Federal_Food,_Drug,_and_Cosmetic_Act
|
| gptkbp:bfsLayer |
4
|